Next Up

Immuno UK: In-Person

29 - 30 September 2022 |

London, UK

29 - 30 September 2022

London, UK

Designing & delivering innovative immunotherapies to transform cancer care.

15 Sep 2022
Thu, 15 September 2022

Upcoming Immuno Takara Bio Webinar

Presented by Takara Bio

Takara Logo
03 Oct 2022
Mon, 03 October 2022

Immuno US: In-Person

Discuss the latest strategies to harness the immune system for the development of innovative therapeutics

01 Nov 2022
Tue, 01 November 2022

Tumour Microenvironment: In-Person

02 Nov 2022
Wed, 02 November 2022

Upcoming Immuno PharmaLegacy Webinar

Presented by PharmaLegacy

Highlights

Render of a T cell with portraits of Paul Rennert and Michael Zaiac
Discussion Group Report
CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.
Edited by Tom Cohen |
23 June 2022
Translational & Preclinical Development
Commentary
14 Jun 2022
Translational & Preclinical Development
Discussion Group Report
Edited by Tom Cohen |
25 May 2022
Autoimmunity & Immunology

In-Depth

Discussion Group Report
CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.
23 June 2022
Commentary
Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.
14 June 2022
Discussion Group Report
Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.
25 May 2022
Insight Article
What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?
20 May 2022

[sponsor section - bespoke content]

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno